The growth capital will be used to expand BardyDx's sales force and monitoring services, advance research and development programs, and accelerate development of artificial intelligence diagnostic capabilities.
BardyDx is an innovator in digital health and remote patient monitoring, with a focus on providing diagnostically-accurate and patient-friendly cardiac patch and other monitors to the industry.
The company's Carnation Ambulatory Monitor (CAM) patch is a non-invasive, P-wave centric ambulatory cardiac monitor and arrhythmia detection device that is designed to improve patient compliance for men, women, and children through its lifestyle-enabling patch design.
SV Health Investors is a healthcare and life sciences venture capital and growth equity firm that targets early-stage opportunities in biotechnology; early-stage and revenue-stage opportunities in medical devices; and growth equity investments for later-stage businesses in healthcare services and digital health.
Health Enterprise Partners invests primarily in privately held, middle market companies in health care services and health care information technology.
The company seeks to invest in companies that improve the quality of the patient experience, expand access, and reduce the cost of health care.
Ascension Ventures is a strategic healthcare venture firm that constructs and manages a strategic portfolio of investments that deliver venture-level investment returns, have the potential to transform the healthcare industry, and significantly enhance the experience for patients, their families and their caregivers.
AnHorn Medicines reports positive results from US Phase I trial of AH-001
ArkBio commences Phase II clinical trial of AK0610
Curasight advances Phase 2 prostate cancer trial with Curium partnership
Thermo Fisher Scientific to acquire Clario Holdings, expanding clinical data capabilities
Hemogenyx Pharmaceuticals advances HG-CT-1 trial and opens paediatric recruitment
Rx to Go receives ACHC re-accreditation for pharmacy services
Shanton Pharma completes SAP-001 End-of-Phase 2 meeting with US FDA
Fibronostics completes Stone Clinical Laboratories acquisition